Press Releases
Drug Research
BioInvent’s BI-1206 could improve treatment in several cancers
Alexander Eggermont, MD, PhD, Chief Scientific Officer at the Princess Máxima Center and renowned expert in immunotherapy showcased the broad potential of BI-1206 in enhancing checkpoint inhibitors in solid cancers in a KOL event hosted by BioInvent on July...
Clinical Trials
Novartis launches first-of-its-kind not-for-profit portfolio of medicines for symptomatic treatment of COVID-19
Novartis announced a new initiative to help patients in low-income and lower-middle-income countries (LIC; LMIC) access affordable medicines to treat the major symptoms of COVID-19 – a critical need in the absence of a vaccine or curative treatment. Inflammation...
Press Releases
Vesigen Therapeutics launches with USD 28.5 million Series A investment led by Leaps by Bayer and Morningside Ventures
Vesigen Therapeutics launched with the objective to overcome the hurdle of targeted intracellular drug delivery of next-generation therapeutics, such as CRISPR-cas9, RNA molecules and other therapeutic proteins, by using a proprietary delivery technology. Leaps by Bayer and Morningside Ventures...
Clinical Trials
Biogen Plans to Initiate Phase 4 Study Evaluating Benefit of SPINRAZA in Patients Treated with Zolgensma
Biogen Inc announced it plans to initiate a global Phase 4 clinical study, RESPOND, to examine the clinical benefit and assess the safety of SPINRAZA® (nusinersen) in infants and children with spinal muscular atrophy (SMA) who still have unmet...
Drug Research
Catalent Biologics to Invest $30 Million to Create European Clinical Manufacturing Center of Excellence in France
Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, announced that it plans to invest $30 million (€27 million) at its facility in Limoges,...
Drug Research
GSK and CureVac announce strategic mRNA technology collaboration
GlaxoSmithKline plc and CureVac announced the signing of a strategic collaboration agreement for the research, development, manufacturing and commercialisation of up to five mRNA-based vaccines and monoclonal antibodies (mAbs) targeting infectious disease pathogens. The collaboration complements GSK’s existing mRNA...
Press Releases
Stevanato Group signs an agreement with COLANAR for lab-scale fill & finish capabilities
Italian-based Stevanato Group, a leading producer of glass primary packaging and provider of integrated capabilities for drug delivery systems has signed an agreement with COLANAR, a global leader in small-batch pharma filling machines.
Stevanato Group's new US Technology Excellence Center...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read















